《中国细胞与基因治疗产业发展及监管政策解读蓝皮书》发布

Group 1 - The core viewpoint of the article emphasizes that the success of China's cell and gene therapy (CGT) industry will depend on the collaborative development of technological innovation, regulatory science, payment systems, and industry chain maturity [1] - The "Blue Book on the Development and Regulatory Policy Interpretation of China's Cell and Gene Therapy Industry" was released during the conference, highlighting the potential for China to play a more critical role in the global CGT field, ultimately benefiting patients worldwide [1] - Beijing has ranked first in the number of medical device products approved for market in the past three years, and third in the approval of innovative Class 1 drugs, with the medical and health industry in Beijing projected to reach a scale of 1.06 trillion yuan in 2024, representing an 8.7% year-on-year growth [1] Group 2 - Haidian District leverages its strong educational and clinical resources, including 37 higher education institutions and 57 hospitals, to create a "talent highland" for innovation and research in the field of cell and gene therapy [2] - The district is home to several innovative companies focused on CGT drug development, providing continuous innovation momentum for cutting-edge fields [2] - A global future pharmaceutical health industry incubation platform was launched, aimed at promoting the development of four core technology areas: CGT, multi-omics and precision medicine, brain-computer interfaces, and AI healthcare [2] - The establishment of the China Cell and Gene Therapy Alliance (CSGCT Board) aims to create an international platform for scientific research and collaboration, facilitating broader international cooperation and resource sharing in the CGT field [2]